Trade Policy

Experts at a recent summit discussed the complexities and impact of US MFN pricing from a payer perspective and emphasized the importance of a centralized purchaser of drugs to effectively negotiate prices. The potential rise of 'confidential discounts' in Germany was another key talking point.

The trade body, Medicines Australia, has flagged a downturn in new drug launches, attributing it to the effects of President Trump’s trade policies. It has called for “urgent action.”

India has cut GST on active ingredients in drugs like Novartis’s Zolgensma, J&J’s Darzalex and Roche’s Ocrevus. But Trump added a H1B visa brick to his trade wall while US Secretary of State Marco Rubio hinted at a relook at a punitive Russian oil tariff. Scrip considers the impact

As US Secretary of State Marco Rubio hints at reconsideration of a punitive Russian oil tariff, Trump adds an H-1B visa brick to his trade wall and India lowers GST on cancer and rare disease drugs, the Pink Sheet considers the impact.

An executive order has given the go-ahead for US tariffs on Japan to be amended to “zero percent” for generics, just weeks after the EU revealed an effective exemption from its own US tariffs. Meanwhile, a separate order suggests that generics could enjoy broader global exemptions from tariffs.

The US International Trade Commission has banned smart rings from Ultrahuman and RingConn after Oura Health's patent infringement case. Ultrahuman countersued, claiming Oura infringes its intellectual property. Sales and marketing of the affected rings will cease on October 22.

As US-India ties rupture, what could it mean for joint calls by the two nations to de-risk the pharma supply chain and could New Delhi consider non-tariff tools to make a point?

Centrient CEO Rex Clements talks about how the industry landscape is shifting for the European pure-play antibiotics producer, addressing issues including supply-chain security, US tariffs, localized manufacturing and AMR, as well as explaining how the firm is incorporating AI into its plans.

The European generics industry has welcomed news that generic medicines will be exempt from tariffs under the latest EU-US trade agreement.

NAD attorneys find Kendal Nutricare can continue using “natural” ad claims with limits for Kendamil formula but also conclude some research it submitted to support other claims wasn’t appropriate because the studies didn’t test its products.

Europe’s research-based pharma industry group, EFPIA, is pressing EU policymakers to protect innovative medicines after the EU-US trade deal confirmed a 15% tariff on pharmaceutical exports. Generic products, meanwhile, have secured an exemption.

When consumer health and beauty firms announce results for current quarter, they likely will note trend many reported after first quarter, an uptick in revenues and volume due to consumer concern about Trump’s tariffs gambit leading to higher product prices.